Brokers Offer Predictions for Waters’ Q1 Earnings (NYSE:WAT)

Waters Co. (NYSE:WAT) – KeyCorp issued their Q1 2025 earnings estimates for Waters in a research report issued to clients and investors on Monday, March 31st. KeyCorp analyst P. Knight expects that the medical instruments supplier will post earnings of $2.20 per share for the quarter. KeyCorp currently has a “Overweight” rating and a $460.00 target price on the stock. The consensus estimate for Waters’ current full-year earnings is $12.86 per share. KeyCorp also issued estimates for Waters’ Q2 2025 earnings at $2.88 EPS, Q3 2025 earnings at $3.23 EPS, Q4 2025 earnings at $4.45 EPS and FY2026 earnings at $13.83 EPS.

Waters (NYSE:WAT) last announced its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%.

A number of other research analysts have also recently commented on WAT. UBS Group increased their target price on shares of Waters from $405.00 to $410.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Wells Fargo & Company increased their price objective on shares of Waters from $415.00 to $420.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Bank of America lowered their price target on shares of Waters from $430.00 to $410.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Sanford C. Bernstein raised shares of Waters from a “market perform” rating to an “outperform” rating and set a $430.00 target price on the stock in a report on Friday, January 10th. Finally, Scotiabank upgraded shares of Waters from a “sector perform” rating to a “sector outperform” rating and lifted their price target for the stock from $430.00 to $450.00 in a report on Thursday, February 13th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $401.31.

Waters Trading Up 1.7 %

Shares of WAT opened at $362.21 on Tuesday. The business’s fifty day moving average is $384.62 and its 200-day moving average is $373.38. The firm has a market cap of $21.52 billion, a price-to-earnings ratio of 33.82, a PEG ratio of 3.79 and a beta of 1.00. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94. Waters has a 52-week low of $279.24 and a 52-week high of $423.56.

Hedge Funds Weigh In On Waters

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC grew its stake in Waters by 17.8% in the third quarter. Cerity Partners LLC now owns 5,349 shares of the medical instruments supplier’s stock valued at $1,925,000 after acquiring an additional 807 shares during the period. FMR LLC grew its position in Waters by 1.2% in the 3rd quarter. FMR LLC now owns 81,653 shares of the medical instruments supplier’s stock valued at $29,386,000 after purchasing an additional 934 shares during the period. Townsquare Capital LLC acquired a new stake in Waters in the 3rd quarter valued at $229,000. Financial Counselors Inc. bought a new stake in Waters during the 3rd quarter valued at $267,000. Finally, Public Sector Pension Investment Board raised its holdings in Waters by 13.2% during the third quarter. Public Sector Pension Investment Board now owns 2,578 shares of the medical instruments supplier’s stock worth $928,000 after buying an additional 300 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.